Sign In
Buy LXRX
$1.85
-0.0400 (-2.12%)
At Close: Jun 03, 2026
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
08:00am, Wednesday, 03'rd Jun 2026
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups Presentations highlight consistent A1c reductio
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
08:30am, Thursday, 28'th May 2026
THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies G
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
08:30am, Tuesday, 12'th May 2026
THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C.
Lexicon Pharmaceuticals Q1 Earnings Call Highlights
04:12pm, Friday, 08'th May 2026
Lexicon Pharmaceuticals NASDAQ: LXRX executives highlighted progress across late-stage regulatory programs and efforts to bolster the company's financial position during the company's first-quarter 20
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
05:11pm, Thursday, 07'th May 2026
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1
09:55am, Thursday, 07'th May 2026
Lexicon Pharmaceuticals (LXRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago.
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
07:30am, Thursday, 07'th May 2026
SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA ® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
04:05pm, Monday, 04'th May 2026
THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE: HTGC) th
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
08:00am, Thursday, 30'th Apr 2026
THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
08:00am, Friday, 17'th Apr 2026
Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving Average – Here’s Why
02:11am, Tuesday, 31'st Mar 2026
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $1.39 and traded as h
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug
11:35am, Tuesday, 24'th Mar 2026
Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
08:00am, Tuesday, 24'th Mar 2026
Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action Additional analys
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
07:30am, Monday, 23'rd Mar 2026
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
Financial Analysis: Oncotelic Therapeutics (OTCMKTS:OTLC) versus Lexicon Pharmaceuticals (NASDAQ:LXRX)
01:58am, Sunday, 15'th Mar 2026
Oncotelic Therapeutics (OTCMKTS:OTLC - Get Free Report) and Lexicon Pharmaceuticals (NASDAQ: LXRX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will
